Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 293 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR For the RTOG 9408, and this randomized 1,979 patients so you... July 19, 2023 Removing senescent immune cells could be the key to preventing some... June 1, 2023 FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma December 5, 2025 First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... July 5, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Retifanlimab Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... After 5 Years of Follow-Up, the Median PFS Has Yet To...
